The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Potency Assurance for Cellular and Gene Therapy Products." The guidance document provides recommendations to help assure the potency of human cellular therapy or gene therapy (CGT) products at all stages of the product lifecycle. FDA is recommending a comprehensive approach to potency assura
Excerpt shown under fair-use limits. Full text remains with the original publisher.
People in this coverage
Explore their history and attributable record. Being mentioned does not imply endorsement.
Authority AppealThe statement leverages the FDA's regulatory authority to lend weight to the guidance.
Technical LanguageUses specialized terminology to convey thoroughness and scientific rigor.
Future OrientationFrames the guidance as a roadmap for ongoing and future product development activities.
Context
AI analysis
Missing context
The excerpt does not provide information on how the guidance will be implemented by industry, any timelines for compliance, potential challenges for manufacturers, or the expected impact on product approval processes.
Important context
The guidance is a final FDA document that supersedes a draft issued on December 28, 2023, indicating that the agency has completed its rulemaking process for potency assurance in CGT products.
Opinion vs. reporting
AI analysis
The text is purely informational and does not contain opinion; it reports the FDA's announcement and outlines the content of the guidance.